Serum adiponectin levels in adults with Prader-Willi syndrome are independent of anthropometrical parameters and do not change with GH treatment.

What Was Tested

The paper reports a study of Human Growth Hormone, published as a randomized controlled trial.

The researchers therefore found it of interest to measure adiponectin levels in PWS.

Who Took Part

According to the abstract, 17 adults were involved.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

17 adults, nine men and eight women, 17 to 32 years of age, with a mean body mass index (BMI) of 35+/-3.2 kg/m2 participated.

At baseline, serum total adiponectin levels in the PWS patients were compared with 25 lean and 34 obese controls.

How the Study Was Run

The design is described as randomized and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Human Growth Hormone and who got the comparison, which limits bias.

A placebo (an inactive look-alike) gave the Human Growth Hormone group a baseline to be compared against.

What Was Measured

Topics PubMed links to this paper include Adiponectin, Body Composition, Human Growth Hormone, Intercellular Signaling Peptides and Proteins, Obesity and Prader-Willi Syndrome.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Human Growth Hormone in 17 adults.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2004 (European journal of endocrinology), a journal based in England.

More context: the related Exogenous HGH, sermorelin & older GHRPs (why they're passed over) library page, all human trials.